JP2008508859A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508859A5
JP2008508859A5 JP2007513935A JP2007513935A JP2008508859A5 JP 2008508859 A5 JP2008508859 A5 JP 2008508859A5 JP 2007513935 A JP2007513935 A JP 2007513935A JP 2007513935 A JP2007513935 A JP 2007513935A JP 2008508859 A5 JP2008508859 A5 JP 2008508859A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
pharmaceutical composition
rabies virus
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513935A
Other languages
English (en)
Japanese (ja)
Other versions
JP4768730B2 (ja
JP2008508859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/052410 external-priority patent/WO2005118644A2/en
Publication of JP2008508859A publication Critical patent/JP2008508859A/ja
Publication of JP2008508859A5 publication Critical patent/JP2008508859A5/ja
Application granted granted Critical
Publication of JP4768730B2 publication Critical patent/JP4768730B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007513935A 2004-05-27 2005-05-26 狂犬病ウイルスを中和することができる結合分子およびそれらの用途 Expired - Fee Related JP4768730B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US57502304P 2004-05-27 2004-05-27
US60/575,023 2004-05-27
EP2004050943 2004-05-27
EPPCT/EP2004/050943 2004-05-27
EPPCT/EP2004/051661 2004-07-29
EP2004051661 2004-07-29
EPPCT/EP2004/052286 2004-09-23
EP2004052286 2004-09-23
EP2004052772 2004-11-03
EPPCT/EP2004/052772 2004-11-03
EPPCT/EP2005/050310 2005-01-25
EP2005050310 2005-01-25
EPPCT/EP2005/050953 2005-03-03
EP2005050953 2005-03-03
PCT/EP2005/052410 WO2005118644A2 (en) 2004-05-27 2005-05-26 Binding molecules capable of neutralizing rabies virus and uses thereof

Publications (3)

Publication Number Publication Date
JP2008508859A JP2008508859A (ja) 2008-03-27
JP2008508859A5 true JP2008508859A5 (enExample) 2008-07-10
JP4768730B2 JP4768730B2 (ja) 2011-09-07

Family

ID=34968690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513935A Expired - Fee Related JP4768730B2 (ja) 2004-05-27 2005-05-26 狂犬病ウイルスを中和することができる結合分子およびそれらの用途

Country Status (22)

Country Link
US (5) US7579446B2 (enExample)
EP (3) EP2314621B1 (enExample)
JP (1) JP4768730B2 (enExample)
KR (2) KR101456770B1 (enExample)
CN (5) CN102212132A (enExample)
AT (1) ATE501171T1 (enExample)
AU (1) AU2005250163B2 (enExample)
BR (1) BRPI0511479C1 (enExample)
CA (1) CA2568162C (enExample)
CU (1) CU23719A3 (enExample)
CY (1) CY1111550T1 (enExample)
DK (1) DK1749029T3 (enExample)
EA (1) EA010785B1 (enExample)
ES (2) ES2468021T3 (enExample)
HR (3) HRP20110320T1 (enExample)
IL (3) IL179586A (enExample)
MX (1) MXPA06013482A (enExample)
NZ (2) NZ550366A (enExample)
PL (3) PL2314621T3 (enExample)
PT (3) PT2314620E (enExample)
RS (2) RS53269B (enExample)
WO (1) WO2005118644A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4852046B2 (ja) * 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
AU2006290736B2 (en) * 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008068246A1 (en) * 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
LT2483416T (lt) 2009-10-02 2017-04-25 The Regents Of The University Of California Monokloniniai antikūnai
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
CN103596975A (zh) * 2010-01-04 2014-02-19 印度免疫有限公司 针对狂犬病病毒的重组人二价双链抗体及其用途
EP2894222B8 (en) 2010-02-19 2019-04-24 Japan Science and Technology Agency Human abzyme
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
CN103068851B (zh) * 2010-06-16 2015-03-11 高等教育联邦系统-匹兹堡大学 内质蛋白的抗体及其用途
WO2012128508A2 (ko) * 2011-03-18 2012-09-27 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN103998059B (zh) 2011-09-30 2016-01-20 赛特瑞恩股份有限公司 用于中和狂犬病病毒的结合分子
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN102924571A (zh) * 2012-10-29 2013-02-13 复旦大学 狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
WO2015088256A1 (ko) * 2013-12-12 2015-06-18 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) * 2014-07-01 2015-05-10 Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) * 2015-02-03 2015-07-08 中国食品药品检定研究院 具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
CN114014930A (zh) * 2015-02-13 2022-02-08 索伦托药业有限公司 结合ctla4的抗体治疗剂
KR101969626B1 (ko) * 2015-06-10 2019-04-16 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) * 2017-12-29 2020-04-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
RU2764740C1 (ru) * 2018-08-09 2022-01-20 Бейцзин Уиздомаб Байотекнолоджи Ко., Лтд Биспецифическое антитело против вируса бешенства и его применение
BR112021023897A2 (pt) 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
MX2022014598A (es) * 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
WO2022217054A1 (en) * 2021-04-09 2022-10-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ror1
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用
CN119930826B (zh) * 2023-11-02 2026-07-24 重庆精准生物产业技术研究院有限公司 针对psca的全人源单链抗体及其应用
CN117777282B (zh) * 2023-12-07 2025-03-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒中和抗体及其制备和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ES2062364T3 (es) * 1989-06-08 1994-12-16 Wistar Inst Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
ES2378272T3 (es) 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7071319B2 (en) * 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7329530B2 (en) 2001-06-15 2008-02-12 Crucell Holland B.V. Chimaeric phages
ATE557040T1 (de) * 2001-08-21 2012-05-15 Univ Jefferson Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
NZ537277A (en) * 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
PL2314621T3 (pl) * 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006136601A1 (en) 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
EA017110B1 (ru) * 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. ПИРИМИДИНИЛСУЛЬФОНАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПИРИМИДИНИЛСУЛЬФОНАМИДНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО ИНТЕГРИНОМ α4, СПОСОБ СНИЖЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ВОСПАЛИТЕЛЬНОГО КОМПОНЕНТА ЗАБОЛЕВАНИЯ ИЛИ АУТОИММУННОГО ОТВЕТА
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008068246A1 (en) 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations

Similar Documents

Publication Publication Date Title
JP2010502207A5 (enExample)
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
JP2006526414A5 (enExample)
JP2005511076A5 (enExample)
JP2019511222A5 (enExample)
JP2011250797A5 (enExample)
JP2005503789A5 (enExample)
WO2011020783A3 (en) Targeted immunoconjugates
JP2009537143A5 (enExample)
JP2008515446A5 (enExample)
JP2010516290A5 (enExample)
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
RU2007139915A (ru) Haemophilus influenzae типа в
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
JP2010166916A5 (enExample)
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
HRP20110320T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
WO2010044889A3 (en) Torque teno virus (ttv) isolates and compositions
JP2008536483A5 (enExample)
JP2008525033A5 (enExample)
JP2009520758A5 (enExample)
WO2009079481A3 (en) Methods to diagnose and immunize against the virus causing human merkel cell carcinoma
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof